<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40466424</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8865</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Semergen</Title><ISOAbbreviation>Semergen</ISOAbbreviation></Journal><ArticleTitle>[The role of metformin in the cardiokidney-metabolic patient].</ArticleTitle><Pagination><StartPage>102530</StartPage><MedlinePgn>102530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semerg.2025.102530</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1138-3593(25)00083-8</ELocationID><Abstract><AbstractText>Metformin is a first-line drug in the treatment of type2 diabetes mellitus (T2DM) due to its efficacy, safety, and cost-effectiveness. Its main mechanism of action is the reduction of hepatic gluconeogenesis, improving insulin sensitivity and modulating glucose metabolism. The benefits of metformin are not limited to glycemic control, as it also has cardiovascular effects, reducing the risk of acute myocardial infarction and cardiovascular mortality in people with T2DM. Additionally, it has positive effects on lipid metabolism, metabolic dysfunction-associated liver disease, and pulmonary pathology, as well as potential effects in preventing cancer and neurodegenerative diseases. Its impact on aging and the gut microbiota remains an area of ongoing research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de M&#xe9;dicos de Atenci&#xf3;n Primaria (SEMERGEN). Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arranz Mart&#xed;nez</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Centro de Salud San Blas, Parla, Madrid, Espa&#xf1;a; Grupo de Trabajo de Diabetes, Endocrinolog&#xed;a y Metabolismo, Semergen, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Teixid&#xf3;</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Centro de Salud Burguillos del Cerro, Burguillos del Cerro, Badajoz, Espa&#xf1;a; Grupo de Trabajo de Diabetes, Endocrinolog&#xed;a y Metabolismo, Semergen, Espa&#xf1;a. Electronic address: carlos.teixido92@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ru&#xed;z Garc&#xed;a</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicina de Familia, Centro Universitario Pinto, Pinto, Madrid, Espa&#xf1;a; Grupo de Trabajo de Diabetes, Endocrinolog&#xed;a y Metabolismo, Semergen, Espa&#xf1;a; Grupo de Trabajo de Enfermedades Cardiovasculares, Semergen, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Papel de la metformina en los tiempos del paciente cardiorrenometab&#xf3;lico.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Semergen</MedlineTA><NlmUniqueID>9610769</NlmUniqueID><ISSNLinking>1138-3593</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus tipo2</Keyword><Keyword MajorTopicYN="N">Enfermedades cardiovasculares</Keyword><Keyword MajorTopicYN="N">Insulin resistance</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Metformina</Keyword><Keyword MajorTopicYN="N">Resistencia a la insulina</Keyword><Keyword MajorTopicYN="N">Type2 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>18</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40466424</ArticleId><ArticleId IdType="doi">10.1016/j.semerg.2025.102530</ArticleId><ArticleId IdType="pii">S1138-3593(25)00083-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39157750</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2173-9218</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Farmaceuticos comunitarios</Title><ISOAbbreviation>Farm Comunitarios</ISOAbbreviation></Journal><ArticleTitle>[Probable pharmacological interaction between sulfonylurea and beta-blocker in a patient with DM-II. A case report].</ArticleTitle><Pagination><StartPage>37</StartPage><EndPage>42</EndPage><MedlinePgn>37-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.33620/FC.2173-9218.(2024).11</ELocationID><Abstract><AbstractText>The study presents the case of a 47-year-old woman with type 2 diabetes (T2D), hypertension and anemia, treated with metformin, glyburide, metoprolol, and iron/folic acid. A drug interaction was identified between glyburide and metoprolol, causing symptoms of hypoglycemia in the afternoon. Evaluation using Horn's Drug Interaction Probability Scale (DIPS) suggested a probable interaction. Pharmacokinetic analysis revealed that the time at which the maximum concentrations of both drugs were reached coincided with the onset of symptoms. A new medication schedule was implemented which resolved the symptoms. The drug interaction was attributed to the blockade of adrenergic effects by metoprolol, compromising the ability to counteract the action of insulin released by glybenclamide. The importance of surveillance, informed decision-making and the implementation of preventive strategies is highlighted to ensure the safety and effectiveness of pharmacological treatment in patients with specific clinical conditions, such as T2D and concomitant cardiovascular diseases.</AbstractText><CopyrightInformation>Copyright SEFAC. Sociedad Espa&#xf1;ola de Farmacia Cl&#xed;nica, Familiar y Comunitaria. This article is available from url https://www.farmaceuticoscomunitarios.org/.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Centeno-Hoil</LastName><ForeName>Gregoreo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Farmac&#xe9;utico comunitario. Farmacia Zarzuelo, Benalm&#xe1;dena (M&#xe1;laga). Farmacia Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mousavi</LastName><ForeName>Homa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Farmac&#xe9;utico comunitario. Farmacia Zarzuelo, Benalm&#xe1;dena (M&#xe1;laga). Farmacia Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Probable interacci&#xf3;n farmacol&#xf3;gica entre sulfonilurea y betabloqueante en paciente con DM-II. Un reporte de caso.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Farm Comunitarios</MedlineTA><NlmUniqueID>9918592388706676</NlmUniqueID><ISSNLinking>2173-9218</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>GEB06NHM23</RegistryNumber><NameOfSubstance UI="D008790">Metoprolol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>SX6K58TVWC</RegistryNumber><NameOfSubstance UI="D005905">Glyburide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="Y">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008790" MajorTopicYN="Y">Metoprolol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005905" MajorTopicYN="N">Glyburide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El estudio presenta el caso de una mujer de 47 a&#xf1;os con diabetes tipo 2 (DM-II), hipertensi&#xf3;n y anemia, tratada con metformina, glibenclamida, metoprolol y hierro/&#xe1;cido f&#xf3;lico. Se identific&#xf3; una interacci&#xf3;n farmacol&#xf3;gica entre glibenclamida y metoprolol, causando s&#xed;ntomas de hipoglucemia por la tarde. La evaluaci&#xf3;n mediante la Escala de Probabilidad de Interacciones Farmacol&#xf3;gicas (EPIF) de Horn sugiri&#xf3; una interacci&#xf3;n probable. El an&#xe1;lisis farmacocin&#xe9;tico revel&#xf3; que el tiempo en el cual se alcanzan las concentraciones m&#xe1;ximas de ambos f&#xe1;rmacos coincid&#xed;a con el inicio de los s&#xed;ntomas. Se implement&#xf3; un nuevo horario de medicaci&#xf3;n que resolvi&#xf3; los s&#xed;ntomas. La interacci&#xf3;n farmacol&#xf3;gica se atribuy&#xf3; al bloqueo de los efectos adren&#xe9;rgicos por el metoprolol, comprometiendo la capacidad de contrarrestar la acci&#xf3;n de la insulina liberada por la glibenclamida. Se resalta la importancia de la vigilancia, la toma de decisiones informadas y la implementaci&#xf3;n de estrategias preventivas para garantizar la seguridad y eficacia del tratamiento farmacol&#xf3;gico en pacientes con condiciones cl&#xed;nicas espec&#xed;ficas, como la DM-II y enfermedades cardiovasculares concomitantes.</AbstractText><CopyrightInformation>Copyright SEFAC. Sociedad Espa&#xf1;ola de Farmacia Cl&#xed;nica, Familiar y Comunitaria. This article is available from url https://www.farmaceuticoscomunitarios.org/.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes Mellitus type 2</Keyword><Keyword MajorTopicYN="N">Drug Interactions</Keyword><Keyword MajorTopicYN="N">Glybenclamide</Keyword><Keyword MajorTopicYN="N">Hypoglycemia</Keyword><Keyword MajorTopicYN="N">Metoprolol</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39157750</ArticleId><ArticleId IdType="pmc">PMC11328701</ArticleId><ArticleId IdType="doi">10.33620/FC.2173-9218.(2024).11</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johnson-Rabbett B, Seaquist ER. Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient&#x2010;centered review. J Diabetes. 2019 doi: 10.1111/1753-0407.12933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.12933</ArticleId><ArticleId IdType="pubmed">30983138</ArticleId></ArticleIdList></Reference><Reference><Citation>Micromedex Products. Micromedex Products. 2024.  
 https://www.micromedexsolutions.com/micromedex2/librarian/
</Citation></Reference><Reference><Citation>Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007 doi: 10.1345/aph.1h423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1h423</ArticleId><ArticleId IdType="pubmed">17389673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Zhao J, Qu Y, Sun Q, Li TT, Yan ML. Metoprolol prevents neuronal dendrite remodeling in a canine model of chronic obstructive sleep apnea. Acta Pharmacol. 2020 doi: 10.1038/s41401-019-0323-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-019-0323-8</ArticleId><ArticleId IdType="pmc">PMC7470867</ArticleId><ArticleId IdType="pubmed">31863057</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberne AJM, Korim WS, Sabetghadam A, Llewellyn-Smith IJ. Adrenaline: Insights into its metabolic roles in hypoglycaemia and diabetes. Pharmacol. 2016 doi: 10.1111/bph.13458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13458</ArticleId><ArticleId IdType="pmc">PMC4831313</ArticleId><ArticleId IdType="pubmed">26896587</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes&#x2014;2024. Diabetes Care. 2024 doi: 10.2337/dc24-S009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36602126</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>Randomized clinical trial to evaluate the effect on postprandial glycemia of Nutren Control&#xae;, a glycemia-targeted specialized supplement, compared to standardized breakfast in patients with type-2 diabetes: the CONTROL DIABETES study.</ArticleTitle><Pagination><StartPage>41</StartPage><EndPage>48</EndPage><MedlinePgn>41-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20960/nh.04204</ELocationID><Abstract><AbstractText>Objective: to evaluate the effects of a new glycemia targeted specialized supplement (GTSS) compared to a standard breakfast on postprandial blood glucose (PPG). Methods: patients with type 2 diabetes (T2D) and suboptimal control (A1C between 6.5 and 8.5 %) in monotherapy with metformin were included to this prospective, randomized, crossover trial. The standardized breakfast was isoenergetic compared to the GTSS, differing on macronutrients distribution. Both interventions were used once a day in the morning, each replacing breakfast for 7 consecutive days (14 days of observation). Intermittent scanning continuous glucose monitoring system (isCGM) determined the difference between the interventions regarding the incremental area under the curve (iAUC) of the PPG (3 hours after intervention), as a primary endpoint; secondary endpoints were the difference between the interventions regarding the glycemic peak, postprandial glucose excursion (PPGE), mean blood glucose (MBG) and time in range (TIR). Results: thirty-one T2D patients with ages between 39 and 69 years-old were enrolled. GTSS group had significantly lower iAUC of the PPG compared to standardized breakfast (33.3 [15.0 to 54.0] vs 46.8 [27.3 to 75.1] mg/dL), while also presenting a significantly lower PPG excursion (26.4 &#xb1; 17.2 vs 44.8 &#xb1; 24.4 mg/dL). There was no difference between the intervention periods regarding MBG, TIR and hypoglycemic events. Conclusion: The new GTSS, as a meal replacement in the breakfast, produced a 25 % reduction in the iAUC of the PPG, as accessed by isCGM, in comparison with an isocaloric-standardized meal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zagury</LastName><ForeName>Roberto Luis</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; HealthScience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacativa</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lacativa Servi&#xe7;os M&#xe9;dicos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greg&#xf3;rio</LastName><ForeName>Luis Henrique de</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Instituto Brasil de Pesquisa Cl&#xed;nica (IBPClin).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Val&#xe9;ria Abrah&#xe3;o Schilling</ForeName><Initials>VAS</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; HealthScience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Leticia Fuganti</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; HealthScience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Renata Alexandra Calixto</ForeName><Initials>RAC</Initials><AffiliationInfo><Affiliation>Instituto Brasil de Pesquisa Cl&#xed;nica (IBPClin).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira da Costa</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IBPClin - Instituto Brasil de Pesquisa Cl&#xed;nica (IBPClin).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Luis Augusto Tavares</ForeName><Initials>LAT</Initials><AffiliationInfo><Affiliation>Instituto Brasil de Pesquisa Cl&#xed;nica (IBPClin).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ensayo cl&#xed;nico aleatorizado para evaluar el efecto sobre la glucemia posprandial de Nutren Control&#xae;, un suplemento especializado dirigido a la glucemia, en comparaci&#xf3;n con el desayuno estandarizado en pacientes con diabetes de tipo 2: el estudio CONTROL D.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062408" MajorTopicYN="N">Breakfast</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015190" MajorTopicYN="N">Blood Glucose Self-Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019518" MajorTopicYN="N">Postprandial Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Objetivo: evaluar los efectos de un suplemento especializado en el control de la glucosa (GTSS) frente a un desayuno est&#xe1;ndar sobre la glucemia posprandial (PPG). Metodolog&#xed;a: es un estudio cruzado, prospectivo, aleatorizado en el que se incluyeron a pacientes con diabetes tipo 2 (T2D) con control sub&#xf3;ptimo de la glucemia (HbA1c entre 6,5 y 8,5 %) utilizando monoterapia con metformina. El desayuno estandarizado fue isocal&#xf3;rico en comparaci&#xf3;n con el GTSS y solamente la distribuci&#xf3;n cal&#xf3;rica fue diferente. Ambas intervenciones se utilizaron una vez al d&#xed;a por la ma&#xf1;ana, reemplazando cada una el desayuno durante 7 d&#xed;as consecutivos (14 d&#xed;as de observaci&#xf3;n). Se utiliz&#xf3; el sistema de monitoreo continuo de glucosa (isCGM) para determinar las diferencias entre las intervenciones con respecto al &#xe1;rea bajo la curva (iAUC) de glucosa postprandial (PPG) (3 horas despu&#xe9;s de la intervenci&#xf3;n) como variable principal o primaria; las variables secundarias fueron la diferencia entre las intervenciones con respecto al pico glic&#xe9;mico, la excursi&#xf3;n de glucosa posprandial (PPGE), la glucosa media en sangre (MBG) y el rango de tiempo (TIR). Resultado: se incluyeron treinta y un pacientes con T2D con edades entre 39 y 69 a&#xf1;os. El grupo del GTSS tuvo un &#xe1;rea bajo la curva (iAUC) significativamente m&#xe1;s baja de la PPG en comparaci&#xf3;n con el grupo del desayuno estandarizado (33,3 [15,0 a 54,0] frente a 46,8 [27,3 a 75,1] mg/dL), mientras que tambi&#xe9;n present&#xf3; una PPG significativamente m&#xe1;s baja (26,4 + 17,2 vs. 44,8 + 24,4 mg/dL). No hubo diferencia entre los per&#xed;odos de intervenci&#xf3;n con respecto a la MBG, el TIR y eventos hipogluc&#xe9;micos. Conclusi&#xf3;n: el nuevo GTSS, como sustituto del desayuno, produjo una reducci&#xf3;n de la iAUC de la PPG del 25 %, seg&#xfa;n el isCGM, en comparaci&#xf3;n con un desayuno isocal&#xf3;rico normalizado.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Suplemento diet&#xe9;tico. Glucosa sangu&#xed;nea. Per&#xed;odo posprandial. Diabetes mellitus de tipo 2. Nutrimentos.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36602126</ArticleId><ArticleId IdType="doi">10.20960/nh.04204</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34452834</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8865</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Semergen</Title><ISOAbbreviation>Semergen</ISOAbbreviation></Journal><ArticleTitle>[Management of patient profiles with type2 diabetes mellitus in Primary Care in Spain: CONTROVERTI2 Program].</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>37</EndPage><MedlinePgn>23-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semerg.2021.07.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1138-3593(21)00225-2</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To identify existing controversies in the routine management of patients with T2D and to contrast them with the latest scientific evidence and clinical guidelines, in order to help optimize and homogenize the treatment of patients with T2D in Primary Care (PC) in Spain.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">240 family doctors responded to an online questionnaire about the management of 6 patient profiles with T2D of increasing complexity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main drivers for the antihyperglycemic treatment choice are an HbA1c&gt;10% and the presence of cardiovascular disease (CVD), although in evolved patients, the estimated glomerular filtration rate and the risk of hypoglycemia become more relevant. In newly diagnosed patients with an HbA1c&gt;9%, treatment is still initiated with monotherapy (24%). In patients not controlled with metformin, dipeptidyl peptidase 4 inhibitors (DPP4-I, 54%) or sodium-glucose cotransporter 2 inhibitors (SGLT2-I, 39%) are usually added. On the other hand, type1 glucagon-like peptide receptor agonists (GLP1-RA) are mainly associated with obese patients with T2D. In patients not controlled with metformin+sulfonylurea (SU), SU replacement is preferred to adding a third antihyperglycemic agent to background therapy (77% vs. 23%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">T2D treatment in PC is still focused on HbA1c reduction and treatment safety. Thus, DPP4-I are widely used. SGLT2-I are usually preferred for patients with T2D and CVD and GLP1-RA for patients with T2D and obesity, although their use in PC is low.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Sociedad Espa&#xf1;ola de M&#xe9;dicos de Atenci&#xf3;n Primaria (SEMERGEN). Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Obaya Rebollar</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Centro de Salud La Chopera, Alcobendas, Madrid, Espa&#xf1;a. Electronic address: juancarlosobaya@yahoo.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miravet Jim&#xe9;nez</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centro de Atenci&#xf3;n Primaria Martorell, Martorell, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranbarri Osoro</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Salud Arrasate, Arrasate, Gipuzkoa, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrami&#xf1;ana Barrera</LastName><ForeName>F C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Centro de Salud San Roque, Badajoz, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Soid&#xe1;n</LastName><ForeName>F J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Centro de Salud O Porri&#xf1;o, O Porri&#xf1;o, Pontevedra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cebri&#xe1;n Cuenca</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centro de Salud Cartagena Casco Antiguo, Cartagena, Murcia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Manejo de perfiles de pacientes con diabetes mellitus tipo2 en la pr&#xe1;ctica cl&#xed;nica de la atenci&#xf3;n primaria en Espa&#xf1;a: Programa CONTROVERTI2.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Semergen</MedlineTA><NlmUniqueID>9610769</NlmUniqueID><ISSNLinking>1138-3593</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="Y">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atenci&#xf3;n primaria</Keyword><Keyword MajorTopicYN="N">Cardiovascular prevention</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus tipo 2</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Inhibidores del SGLT2</Keyword><Keyword MajorTopicYN="N">Insuficiencia card&#xed;aca</Keyword><Keyword MajorTopicYN="N">Prevenci&#xf3;n cardiovascular</Keyword><Keyword MajorTopicYN="N">Primary care</Keyword><Keyword MajorTopicYN="N">SGLT2 inhibitors</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34452834</ArticleId><ArticleId IdType="doi">10.1016/j.semerg.2021.07.009</ArticleId><ArticleId IdType="pii">S1138-3593(21)00225-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33784285</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>Risk factors associated with diabetic neuropathy in Mexican patients.</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>199</EndPage><MedlinePgn>189-199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.20000243</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Diabetic neuropathy (DN) is one of the most common complications of type 2 diabetes (T2D) and is a leading cause of lower limb amputation. The aim of the present study was to evaluate the risk factors contributing to DN in Mexican patients through the comparison of T2D patients with and without DN.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This cross-sectional study consisted of 509 subjects from Mexico who were classified as with DN and without DN. DN was assessed according to Douleur Neuropathique 4 questionnaire. Logistic regression analysis was performed to analyze risk factors contributing to DN.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of DN in the studied population was 28.3%. The risk factors associated with DN were T2D duration (odds ratio [OR]: 2.51; 95% confidence interval [CI] 1.36-4.65), glycemic exposure index (OR: 1.82; 95% CI 1.01-3.64), low- and high-density lipoprotein levels (OR: 1.53; 95% CI 1.02-2.31), metformin treatment (OR: 2.08; 95% CI 1.11-3.91), diabetic retinopathy (OR: 1.65; 95% CI 1.07-2.54), and smoking (OR: 1.51; 95% CI 1.00-2.26).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Therefore, the early identification of risk factors for DN development in Mexican population would allow implementing personalized strategies to improve the overall T2D patients' quality of life and reduce healthcare costs in our country.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xe1;nchez-Pozos</LastName><ForeName>Katy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroy-Escutia</LastName><ForeName>Jazm&#xed;n</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaimes-Santoyo</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granados-Silvestre</LastName><ForeName>Ma de Los &#xc1;ngeles</ForeName><Initials>ML&#xc1;</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menjivar</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-L&#xf3;pez</LastName><ForeName>Ma Guadalupe</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Endocrinology, Hospital Ju&#xe1;rez de M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Factores de riesgo asociados a neuropat&#xed;a diab&#xe9;tica en pacientes mexicanos.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003929" MajorTopicYN="Y">Diabetic Neuropathies</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">La neuropat&#xed;a diab&#xe9;tica (ND) es una de las complicaciones m&#xe1;s comunes de la diabetes tipo 2 (DT2). &#xad;.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Investigar los factores de riesgo que contribuyen al desarrollo de ND en poblaci&#xf3;n mexicana con DT2, comparando pacientes diab&#xe9;ticos con y sin ND.</AbstractText><AbstractText Label="M&#xc9;TODO" NlmCategory="UNASSIGNED">Estudio transversal con 509 pacientes mexicanos con DT2, clasificados en dos grupos, con y sin ND. La ND fue diagnosticada con el cuestionario DN4. La identificaci&#xf3;n de los factores de riesgo de ND se realiz&#xf3; mediante un an&#xe1;lisis de regresi&#xf3;n log&#xed;stica.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">La prevalencia de ND en la poblaci&#xf3;n de estudio fue del 28.3%. Los factores de riesgo asociados a ND fueron la duraci&#xf3;n de la DT2 (odds ratio [OR]: 2.51; intervalo de confianza del 95% [IC 95%]: 1.36-4.65), el &#xed;ndice gluc&#xe9;mico (OR: 1.82; IC 95%: 1.01-3.64), las concentraciones bajas de colesterol unido a lipoprote&#xed;nas de alta densidad (OR: 1.53; IC 95%: 1.02-2.31), el tratamiento con metformina (OR: 2.08; IC 95%: 1.11-3.91), la retinopat&#xed;a diab&#xe9;tica (OR: 1.65; IC 95%: 1.07-2.54) y el tabaquismo (OR: 1.51; IC 95%: 1.00-2.26).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">La identificaci&#xf3;n temprana de los factores de riesgo para el desarrollo de ND en poblaci&#xf3;n mexicana permitir&#xe1; implementar estrategias personalizadas para mejorar la calidad de vida de los pacientes con DT2 y disminuir el gasto del sector salud originado por esta complicaci&#xf3;n.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Complicaciones de diabetes</Keyword><Keyword MajorTopicYN="N">Diabetes complications</Keyword><Keyword MajorTopicYN="N">Diabetes tipo 2</Keyword><Keyword MajorTopicYN="N">Diabetic neuropathy</Keyword><Keyword MajorTopicYN="N">Glycemic index</Keyword><Keyword MajorTopicYN="N">Insulin resistance</Keyword><Keyword MajorTopicYN="N">Neuropat&#xed;a diab&#xe9;tica</Keyword><Keyword MajorTopicYN="N">Resistencia a la insulina</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">&#xcd;ndice gluc&#xe9;mico</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33784285</ArticleId><ArticleId IdType="doi">10.24875/CIRU.20000243</ArticleId><ArticleId IdType="pii">j89/2/189</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32384406</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer.</ArticleTitle><Pagination><StartPage>758</StartPage><EndPage>768</EndPage><MedlinePgn>758-768</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001624</ELocationID><Abstract><AbstractText Label="BACKGROUND">Metformin may reduce cancer risk and mortality and improve radiotherapy responses in several malignancies.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to compare tumor responses and prognoses of metformin and nonmetformin groups of diabetic patients receiving neoadjuvant concurrent chemoradiotherapy for rectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective study.</AbstractText><AbstractText Label="SETTING">This study was conducted at a single institution in the Republic of Korea.</AbstractText><AbstractText Label="PATIENTS">Between January 2000 and November 2017, 104 patients with rectal cancer who were taking diabetes medication and treated with neoadjuvant concurrent chemoradiotherapy followed by radical surgery were reviewed. Patients were divided into those taking (n = 62) and not taking metformin (n = 42). Tumor responses, survival, and other outcomes were analyzed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Tumor response, rectal cancer-specific survival, and disease-free survival rates were measured.</AbstractText><AbstractText Label="RESULTS">Tumor regression grade (p = 0.002), pathological complete response (p = 0.037), and N downstaging (p &lt; 0.001) after neoadjuvant concurrent chemoradiotherapy were significantly higher in the metformin group than in the nonmetformin group. In analysis of cancer-specific mortality, metformin use, differentiation (well, moderate vs poor), pathological Union for International Cancer Control stage (3 vs 1-2), ypN stage (1-2 vs 0), and N downstaging (HR, 0.256 (95% CI, 0.082-0.794), p = 0.018; HR, 0.147 (95% CI, 0.031-0.697), p = 0.016; HR, 3.693 (95% CI, 1.283-10.635), p = 0.015; HR, 3.181 (95% CI, 1.155-8.759), p = 0.025, and HR, 0.175 (95% CI, 0.040-0.769), p = 0.021) were significant factors related to mortality in diabetic patients with rectal cancer. In addition, in the multivariate analysis of cancer recurrence, the interaction between metformin use and lymph node downstaging was a significant predictive factor (HR, 0.222 (95% CI, 0.077-0.639); p = 0.005).</AbstractText><AbstractText Label="LIMITATIONS">This was a small retrospective study conducted at a single institution.</AbstractText><AbstractText Label="CONCLUSIONS">Metformin use was associated with better tumor responses and cancer-specific survival, as well as a lower risk of cancer recurrence, in patients with diabetes mellitus who had lymph node downstaging after neoadjuvant concurrent chemoradiotherapy in rectal cancer. See Video Abstract at http://links.lww.com/DCR/B185. BENEFICIO EN SUPERVIVENCIA CON METFORMINA A TRAV&#xc9;S DE UNA MEJOR RESPUESTA TUMORAL CON QUIMIORRADIOTERAPIA CONCURRENTE NEOADYUVANTE EN C&#xc1;NCER RECTAL: La metformina puede reducir el riesgo de c&#xe1;ncer y la mortalidad y mejorar las respuestas a la radioterapia en varios tumores malignos.Comparar las respuestas tumorales y los pron&#xf3;sticos de los grupos con metformina y sin metformina de pacientes diab&#xe9;ticos que reciben quimiorradioterapia concurrente neoadyuvante para c&#xe1;ncer de recto.Estudio retrospectivo.Instituci&#xf3;n &#xfa;nica en la Rep&#xfa;blica de Corea.Se revisaron 104 pacientes entre enero de 2000 y noviembre de 2017, con c&#xe1;ncer rectal que tomaban medicamentos para diabetes y que fueron tratados con quimiorradioterapia concurrente neoadyuvante seguida de cirug&#xed;a radical. Los pacientes se dividieron en aquellos que tomaban (n = 62) y los que no tomaban metformina (n = 42). Se analizaron las respuestas tumorales, la supervivencia y otros resultados.Se midieron las tasas de la respuesta tumoral, la supervivencia espec&#xed;fica de c&#xe1;ncer rectal y de la supervivencia libre de enfermedad.El grado de regresi&#xf3;n tumoral (p = 0.002), la remisi&#xf3;n patol&#xf3;gica completa (p = 0.037) y la reducci&#xf3;n de la etapa N (p &lt; 0.001) despu&#xe9;s de la quimiorradioterapia concurrente neoadyuvante fueron significativamente mayores en el grupo de metformina que en el grupo sin metformina. En el an&#xe1;lisis de la mortalidad espec&#xed;fica por c&#xe1;ncer, el uso de metformina, la diferenciaci&#xf3;n (bien, moderada vs pobre), el estadio patol&#xf3;gico UICC (3 vs 1-2), el estadio ypN (1-2 vs 0) y la disminuci&#xf3;n de la etapa N (hazard ratios [intervalos de confianza 95%]: 0.256 [0.082-0.794], p = 0.018; 0.147 [0.031-0.697], p = 0.016; 3.693 [1.283-10.635], p = 0.015; 3.181 [1.155-8.759], p = 0.025 y 0.175 [0.040-0.769], p = 0.021, respectivamente) fueron factores significativos relacionados con la mortalidad en pacientes diab&#xe9;ticos con c&#xe1;ncer rectal. Adicionalmente, en el an&#xe1;lisis multivariado de la recurrencia del c&#xe1;ncer, la interacci&#xf3;n entre el uso de metformina y la disminuci&#xf3;n de la etapa ganglionar (N) fue un factor predictivo significativo (hazard ratios [intervalos de confianza del 95%]: 0.222 [0.077-0.639]; p = 0.005).Este fue un estudio retrospectivo peque&#xf1;o realizado en un solo instituto.El uso de metformina se asoci&#xf3; con mejores respuestas tumorales y supervivencia espec&#xed;fica de c&#xe1;ncer, as&#xed; como un menor riesgo de recurrencia del c&#xe1;ncer, en pacientes con disminuci&#xf3;n de la etapa ganglionar (N) despu&#xe9;s de quimiorradioterapia concurrente neoadyuvante en pacientes con c&#xe1;ncer rectal y diabetes. Consulte Video Resumen en http://links.lww.com/DCR/B185. (Traducci&#xf3;n-Dr. Jorge Silva Velazco).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jung Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin Ha</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ye Hyun</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Soo Jung</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheon</LastName><ForeName>Jae Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Won Ho</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Il</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Cancer Prevention Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2020 Jun;63(6):718-719. doi: 10.1097/DCR.0000000000001669.</RefSource><PMID Version="1">32384400</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32384406</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001624</ArticleId><ArticleId IdType="pii">00003453-202006000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12:CD008368.</Citation></Reference><Reference><Citation>Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554&#x2013;1562.</Citation></Reference><Reference><Citation>Gavioli M, Luppi G, Losi L, et al. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum. 2005;48:1851&#x2013;1857.</Citation></Reference><Reference><Citation>Garajov&#xe1; I, Di Girolamo S, de Rosa F, et al. Neoadjuvant treatment in rectal cancer: actual status. Chemother Res Pract. 2011;2011:839742.</Citation></Reference><Reference><Citation>Roh MS, Colangelo LH, O&#x2019;Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124&#x2013;5130.</Citation></Reference><Reference><Citation>Caudle AS, Kim HJ, Tepper JE, et al. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol. 2008;15:1931&#x2013;1936.</Citation></Reference><Reference><Citation>Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56:1304&#x2013;1319.</Citation></Reference><Reference><Citation>Pernicova I, Korbonits M. Metformin&#x2013;mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143&#x2013;156.</Citation></Reference><Reference><Citation>DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294&#x2013;1301.</Citation></Reference><Reference><Citation>Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36:632&#x2013;640.</Citation></Reference><Reference><Citation>Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33:322&#x2013;326.</Citation></Reference><Reference><Citation>Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620&#x2013;1625.</Citation></Reference><Reference><Citation>Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34:2323&#x2013;2328.</Citation></Reference><Reference><Citation>Mei ZB, Zhang ZJ, Liu CY, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One. 2014;9:e91818.</Citation></Reference><Reference><Citation>Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304&#x2013;1305.</Citation></Reference><Reference><Citation>Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131:752&#x2013;759.</Citation></Reference><Reference><Citation>Expert Consultation WHO; WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157&#x2013;163.</Citation></Reference><Reference><Citation>KSAR Study Group for Rectal Cancer. Essential items for structured reporting of rectal cancer MRI: 2016 consensus recommendation from the Korean Society of Abdominal Radiology. Korean J Radiol. 2017;18:132&#x2013;151.</Citation></Reference><Reference><Citation>Siddiqui MR, Bhoday J, Battersby NJ, et al. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol. 2016;22:8414&#x2013;8434.</Citation></Reference><Reference><Citation>Kim DJ, Kim JH, Lim JS, et al. Restaging of rectal cancer with MR imaging after concurrent chemotherapy and radiation therapy. Radiographics. 2010;30:503&#x2013;516.</Citation></Reference><Reference><Citation>Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373&#x2013;1379.</Citation></Reference><Reference><Citation>Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig Liver Dis. 2012;44:1042&#x2013;1047.</Citation></Reference><Reference><Citation>Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23:991&#x2013;1008.</Citation></Reference><Reference><Citation>Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462&#x2013;1472.</Citation></Reference><Reference><Citation>Tobi M, Yang Y-X, Antaki F, Rambus M, Lawson MJ. Mo1914 thiazolidinediones but not metformin significantly reduce colorectal neoplastic lesions in diabetics at risk for colorectal neoplasia. Gastroenterology. 2014;146:S690.</Citation></Reference><Reference><Citation>Tseng YH, Tsan YT, Chan WC, Sheu WH, Chen PC. Use of an &#x3b1;-glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based cohort study. Diabetes Care. 2015;38:2068&#x2013;2074.</Citation></Reference><Reference><Citation>Skinner HD, Crane CH, Garrett CR, et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013;2:99&#x2013;107.</Citation></Reference><Reference><Citation>Oh BY, Park YA, Huh JW, et al. Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. J Cancer Res Clin Oncol. 2016;142:1377&#x2013;1385.</Citation></Reference><Reference><Citation>Zanders MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van de Poll-Franse LV. Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer. 2015;113:403&#x2013;410.</Citation></Reference><Reference><Citation>Rega D, Pecori B, Scala D, et al. Evaluation of tumor response after short-course radiotherapy and delayed surgery for rectal cancer. PLoS One. 2016;11:e0160732.</Citation></Reference><Reference><Citation>Magri KD, Bin FC, Formiga FB, et al. Impact of neoadjuvant therapy in downstaging of lower rectal adenocarcinoma and the role of pelvic magnetic resonance in staging. Rev Col Bras Cir. 2016;43:102&#x2013;109.</Citation></Reference><Reference><Citation>Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology. 2010;254:170&#x2013;178.</Citation></Reference><Reference><Citation>Koeberle D, Burkhard R, von Moos R, et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008;98:1204&#x2013;1209.</Citation></Reference><Reference><Citation>Das P, Skibber JM, Rodriguez-Bigas MA, et al. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006;29:219&#x2013;224.</Citation></Reference><Reference><Citation>Smith KD, Tan D, Das P, et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg. 2010;251:261&#x2013;264.</Citation></Reference><Reference><Citation>Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770&#x2013;1776.</Citation></Reference><Reference><Citation>Collette L, Bosset JF, den Dulk M, et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379&#x2013;4386.</Citation></Reference><Reference><Citation>Fietkau R, Barten M, Klautke G, et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum. 2006;49:1284&#x2013;1292.</Citation></Reference><Reference><Citation>Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109:1750&#x2013;1755.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>